Leonhard SE, van der Eijk AA, Andersen H, Antonini G, Arends S, Attarian S et al (2022) An international perspective on preceding infections in Guillain-Barré Syndrome. Neurology 99:e1299–e1313

Article  PubMed  Google Scholar 

Jacobs BC, Rothbarth PH, van der Meché FGA, Herbrink P, Schmitz PIM, de Klerk MA, van Doorn PA (1998) The spectrum of antecedent infections in Guillain-Barré syndrome. Neurology 51:1110–1115

Article  CAS  PubMed  Google Scholar 

Caudie C, Quittard Pinon A, Taravel D, Sivadon-Tardy V, Orlikowski D, Rozenberg F et al (2011) Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients. J Neurol 258:1958–1964

Article  CAS  PubMed  Google Scholar 

Styczynski AR, Malta JMAS, Krow-Lucal ER, Percio J, Nóbrega ME, Vargas A et al (2017) Increased rates of Guillain-Barré syndrome associated with Zika virus outbreak in the Salvador metropolitan area, Brazil. PLOS Neglect Tropic Dis 11:e0005869

Article  Google Scholar 

Laman JD, Huizinga R, Boons GJ, Jacobs BC (2022) Guillain-Barré syndrome: expanding the concept of molecular mimicry. Trends Immunol 43:296–308

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lleixà C, Martín-Aguilar L, Pascual-Goñi E, Franco T, Caballero M, de Luna N et al (2021) Autoantibody screening in Guillain-Barré syndrome. J Neuroinflammation 18:251

Article  PubMed  PubMed Central  Google Scholar 

Kaida K, Ariga T, Yu RK (2009) Antiganglioside antibodies and their pathophysiological effects on Guillain-Barré syndrome and related disorders–a review. Glycobiology 19:676–692

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tam CC, Rodrigues LC, Petersen I, Islam A, Hayward A, O’Brien SJ (2006) Incidence of Guillain-Barré syndrome among patients with campylobacter infection: a general practice research database study. J Infect Dis 194:95–97

Article  PubMed  Google Scholar 

McCarthy N, Giesecke J (2001) Incidence of Guillain-Barré syndrome following infection with Campylobacter jejuni. Am J Epidemiol 153:610–614

Article  CAS  PubMed  Google Scholar 

van Doorn PA, Van den Bergh PYK, Hadden RDM, Avau B, Vankrunkelsven P, Attarian S et al (2023) European Academy of Neurology/Peripheral nerve Society Guideline on diagnosis and treatment of Guillain-Barré syndrome. Eur J Neurol 30:3646–3674

Article  PubMed  Google Scholar 

Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WCJ, van Gelder T, van Toorenenbergen AW et al (2009) Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66:597–603

Article  CAS  PubMed  Google Scholar 

Lünemann JD, Quast I, Dalakas MC (2016) Efficacy of intravenous immunoglobulin in neurological diseases. Neurotherapeutics 13:34–46

Article  PubMed  Google Scholar 

van Sorge NM, van den Berg LH, Geleijns K, van Strijp JA, Jacobs BC, van Doorn PA et al (2003) Anti–GM1 IgG antibodies induce leukocyte effector functions via Fcγ receptors. Ann Neurol 53:570–579

Article  PubMed  Google Scholar 

He L, Zhang G, Liu W, Gao T, Sheikh KA (2015) Anti-ganglioside antibodies induce nodal and axonal injury via Fcγ receptor-mediated inflammation. J Neurosci 35:6770

Article  CAS  PubMed  PubMed Central  Google Scholar 

Galeotti C, Kaveri SV, Bayry J (2017) IVIG-mediated effector functions in autoimmune and inflammatory diseases. Int Immunol 29:491–498

Article  CAS  PubMed  Google Scholar 

Nagelkerke SQ, Kuijpers TW (2014) Immunomodulation by IVIg and the role of Fc-gamma receptors: classic mechanisms of action after all? Front Immunol 5:674

PubMed  Google Scholar 

Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW (2019) Genetic variation in low-to-medium-affinity Fcγ receptors: functional consequences, disease associations, and opportunities for personalized medicine. Front Immunol. 10:2237

Article  CAS  PubMed  PubMed Central  Google Scholar 

Breunis WB, van Mirre E, Bruin M, Geissler J, de Boer M, Peters M et al (2008) Copy number variation of the activating FCGR2C gene predisposes to idiopathic thrombocytopenic purpura. Blood 111:1029–1038

Article  CAS  PubMed  Google Scholar 

Zhu X-W, Wang Y, Wei Y-H, Zhao P-P, Wang X-B, Rong J-J et al (2016) Comprehensive Assessment of the Association between FCGRs polymorphisms and the risk of systemic lupus erythematosus: evidence from a meta-analysis. Sci Rep 6:31617

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nagelkerke SQ, Tacke CE, Breunis WB, Tanck MWT, Geissler J, Png E et al (2019) Extensive ethnic variation and linkage disequilibrium at the FCGR2/3 locus: different genetic associations revealed in Kawasaki disease. Front Immunol 10:185

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hayat S, Babu G, Das A, Howlader ZH, Mahmud I, Islam Z (2020) Fc-gamma IIIa-V158F receptor polymorphism contributes to the severity of Guillain-Barre syndrome. Ann Clin Transl Neurol 7:1040–1049

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuitwaard K, van Doorn PA, Bengrine T, van Rijs W, Baas F, Nagelkerke SQ et al (2021) Genetic biomarkers for intravenous immunoglobulin response in chronic inflammatory demyelinating polyradiculoneuropathy. Eur J Neurol 28:1677–1683

Article  PubMed  Google Scholar 

Asbury AK, Cornblath DR (1990) Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27(Suppl):S21–S24

Article  PubMed  Google Scholar 

van der Meché FG, Schmitz PI (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 326:1123–9

Article  PubMed  Google Scholar 

The Dutch Guillain-Barré Study G (1994) Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: A pilot study. Annals Neurol 35:749–52.

Van Koningsveld R, Schmitz PI, Ang CW, Groen J, Osterhaus AD, Van der Meché FG, Van Doorn PA (2002) Infections and course of disease in mild forms of Guillain-Barré syndrome. Neurology 58:610–614

Article  PubMed  Google Scholar 

van Koningsveld R, Schmitz PI, Meché FG, Visser LH, Meulstee J, van Doorn PA (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 363:192–196

Article  PubMed  Google Scholar 

Ruts L, Drenthen J, Jongen JLM, Hop WCJ, Visser GH, Jacobs BC et al (2010) Pain in Guillain-Barré syndrome. Neurology 75:1439–1447

Article  CAS  PubMed  Google Scholar 

Walgaard C, Jacobs BC, Lingsma HF, Steyerberg EW, van den Berg B, Doets AY et al (2021) Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 20:275–283

Article  CAS  PubMed  Google Scholar 

Tsang ASMW, Nagelkerke SQ, Bultink IE, Geissler J, Tanck MW, Tacke CE et al (2016) Fc-gamma receptor polymorphisms differentially influence susceptibility to systemic lupus erythematosus and lupus nephritis. Rheumatology (Oxford) 55:939–948

Article  Google Scholar 

Hadden RDM, Cornblath DR, Hughes RAC, Zielasek J, Hartung HP, Toyka KV et al (1998) Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 44:780–788

Article  CAS  PubMed  Google Scholar 

Thomma RCM, Fokke C, Walgaard C, Vermeulen-de Jongh DMC, Tio-Gillen A, van Rijs W et al (2023) High and persistent anti-GM1 antibody titers are associated with poor clinical recovery in Guillain-Barré syndrome. Neurol Neuroimmunol Neuroinflamm 10:e200107

Article  PubMed  PubMed Central  Google Scholar 

Ang CW, Krogfelt K, Herbrink P, Keijser J, van Pelt W, Dalby T et al (2007) Validation of an ELISA for the diagnosis of recent Campylobacter infections in Guillain-Barré and reactive arthritis patients. Clin Microbiol Infect 13:915–922